5-AMINOLEVULINIC ACID (ALA)-INDUCED PROTOPORPHYRIN-IX FLUORESCENCE AND PHOTODYNAMIC EFFECTS IN THE RAT BLADDER - AN IN-VIVO STUDY COMPARINGORAL AND INTRAVESICAL ALA ADMINISTRATION
Sc. Chang et al., 5-AMINOLEVULINIC ACID (ALA)-INDUCED PROTOPORPHYRIN-IX FLUORESCENCE AND PHOTODYNAMIC EFFECTS IN THE RAT BLADDER - AN IN-VIVO STUDY COMPARINGORAL AND INTRAVESICAL ALA ADMINISTRATION, Lasers in surgery and medicine, 20(3), 1997, pp. 254-264
Background and Objective: Photodynamic therapy (PDT) using 5-aminolevu
linic acid (ALA)-induced protoporphyrin IX (PpIX) for sensitization is
a promising treatment for carcinoma in situ and diffuse premalignant
changes of the bladder. We studied the biodistribution of PpIX in a ra
nge of tissues with oral and intravesical routes of administration of
ALA and compared the photodynamic effects on bladder and skin. Study D
esign/Materials and Methods: Normal Wistar rats were given oral or int
ravesical ALA and PpIX levels in the liver, kidney, skin, and bladder
measured by fluorescence microscopy on tissue sections. At the time of
maximum PpIX levels, the bladder and skin on the back were illuminate
d with light at 630 nm and the PDT effects compared. Results: PpIX flu
orescence in the urothelium after 200 mg/kg given intravesically was c
omparable to that found after 100 mg/kg orally. The ratio of PpIX leve
ls between the urothelium and the underlying muscle was the same for b
oth routes of administration, although there appeared to be more selec
tivity of urothelial PDT necrosis after intravesical administration. S
kin photosensitization was greater after oral ALA, the epidermal PpIX
level being three times higher than after intravesical administration
for comparable urothelial levels and the PDT effect being more marked.
Conclusions: Intravesical instillation is preferable to oral administ
ration of ALA for PDT ablation of the urothelium of the rat bladder wi
thout damage to the underlying tissue layers and for minimizing skin p
hotosensitivity. The technique is now ready for clinical trials. (C) 1
997 Wiley-Liss, Inc.